Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces the upcoming presentation of new data on its lead clinical product candidate, PH-762, at the Annual Meeting of the Society of Clinical Oncology (ASCO). PH-762, an INTASYL compound, is being studied in a US clinical trial for specific skin cancers. The open-label Phase 1b clinical study aims to assess safety and efficacy in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The data will be presented by Dr. Mary Spellman at ASCO in Chicago, Illinois on June 1, 2024.
Phio Pharmaceuticals Corp. presents new data on its lead product candidate, PH-762, showcasing progress in the INTASYL™ siRNA gene silencing technology for improved tumor cell killing by immune cells.
The focus on dermatological poster presentation signifies Phio's commitment to developing innovative solutions for skin cancers, addressing unmet medical needs for Stages 1 and 2 cutaneous squamous cell carcinoma with no approved treatments currently available.
The presentation at ASCO highlights Phio's active involvement in the scientific community and commitment to advancing cancer treatment through intratumoral immunotherapy developments.
The clinical trial results for PH-762 are pending, leaving uncertainties regarding the safety and efficacy outcomes for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
The lack of approved drug products for Stages 1 and 2 cutaneous squamous cell carcinoma underscores the challenging landscape for treatment options in these specific cancer stages.
-Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentation
MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead product candidate, PH-762, an INTASYL compound.
PH-762 is currently being studied in a US clinical trial to assess safety and efficacy in specific skin cancers. (NCT 06014086). This open-label Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of IT PH-762 in Stages 1,2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma. Stages 1 and 2 cSCC represent
The data will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, Illinois.
Title: INTASYL™ PH-762: PD-1 Intratumoral Immunotherapy for Cutaneous Carcinoma
| Poster Number: | TPS9620 | |
| Topic: | Melanoma/Skin Cancer | |
| Presenting Author: | Mary Spellman, M.D. | |
| Date and Time: | June 1, 2024: 1:30-4:30 PM CDT | |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company’s website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
ir@phiopharma.com
PR Contact
Michael Adams
Bridge View Media
adams@bridgeviewmedia.com
FAQ
What is the focus of Phio Pharmaceuticals' upcoming presentation at ASCO?
What is the purpose of the open-label Phase 1b clinical study (NCT 06014086) on PH-762?
Who will be presenting the data on INTASYL™ PH-762 at ASCO?
